BROLUCIZUMAB FOR WET-AGED RELATED MACULAR DEGENERATION PATIENTS : TOO GOOD TO BE TRUE
Abstract
Introduction & Objective: Brolucizumab is the newest anti-vascular endothelial growth factor (anti-VEGF) drug. It showed superior anatomic outcomes compared to other anti-VEGF and noniferiority best corrected visual acuity (BCVA) results for Wet-Aged Related Macular Degeneration (Wet-AMD) patients. In Yogyakarta, its been only used in few patients and we want to report the Effectiveness and safety of brolucizumab in Wet-AMD patients in Yogyakarta.
Method: In this retrospective study, all neovascular AMD (nAMD) Patients who underwent brolucizumab intravitreal injections between December 2021 and January 2023 at YAP Eye Hospital were studied. Patient’s demographic data, before and after intravitreal brolucizumab injections (central subfield thickness, intraocular pressure and BCVA) were assessed.
Result :This study included 6 eyes of 6 patients ( 3 women) with a mean age of 69.5 years old. The mean follow- up period was 27 ± 10.1 weeks after the first injection of brolucizumab. Three patients were naïve nAMD patient, never got any intravitreal injections and three anti-VEGF experienced nAMD patients with ranibizumab or aflibercept injections prior to brolucizumab. Mean BCVA at baseline (before brolucizumab injection) was 0.12 decimal (6/48) and was 0.29 decimal (6/20) at the last follow-up. Five out of six patients visual acuity were improved,one patient had constant bcva. Four out of six patient central subfield thickness were reduced, none of the patient intraocular pressure increased over 21 mmhg. None of the patient reported any signs of inflammation, vasculitis, or any other ocular or systemic adverse effects.
Conclusion :This limited data demonstrated that brolucizumab was safe and effective in stabilizing BCVA for both of nAMD patients who had undergone previous treatment with other anti-VEGFs agents and naive. Future larger multicenter collaborative studies are warranted.
Full text article
References
Brad H. Feldman, M.D., Vinay A. Shah M.D., Vinay A. Shah M.D., Leo A. Kim, MD, PhD, Koushik Tripathy, MD (AIIMS), FRCS (Glasgow), Jonathan C. Tsui, MD, Yasser M. Elshatory M. Age-Related Macular Degeneration. In: American Academy of Ophtalmology. 2022.
Tien Wong, MD P, Usha Chakravarthy, MD P, Ronald Klein, MD M, Paul Mitchell, MD P, Gergana Zlateva P, Ronald Buggage M, et al. The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2008;115(116–126).
Wolf AT, Harris A, Oddone F, Siesky B, Verticchio Vercellin A, Ciulla TA. Disease progression pathways of wet AMD: opportunities for new target discovery. Expert Opin Ther Targets. 2022;26(1):5–12.
Sharma A, Kumar N, Parachuri N, Sadda SR, Corradetti G, Heier J, et al. Brolucizumab—early real-world experience: BREW study. Eye [Internet]. 2021;35(4):1045–7. Available from: http://dx.doi.org/10.1038/s41433-020-1111-x
Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-erfurth U, Brown DM, et al. HAWK and HARRIER?: Phase 3 , Multicenter , Randomized , Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology [Internet]. 2020;127(1):72–84. Available from: https://doi.org/10.1016/j.ophtha.2019.04.017
Thomas CJ, Mirza RG, Gill MK, Frcs C. Age-Related Macular Degeneration. Med Clin NA [Internet]. 2021;105(3):473–91. Available from: https://doi.org/10.1016/j.mcna.2021.01.003
Schmidt-Erfurth U, Chong V, Loewenstein A et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists. Br J Ophthalmol. 2014;98:1144–67.
Boulanger-Scemama E, Querques G, About F et al. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015;38:620–7.
Ferrante N, Ritrovato D, Bitonti R, Furneri G. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy. BMC Health Serv Res [Internet]. 2022;22(1):1–11. Available from: https://doi.org/10.1186/s12913-022-07972-w
Authors
Copyright (c) 2024 Tania Purbonegoro, M. Eko Prayogo, A. Nurini Agni, Tri Wahyu W., Supanji Supanji, Firman S.W., M. Bayu Sasongko
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.